BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Open-Angle Glaucoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Open-Angle Glaucoma\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04499248-11139@assetmemo.bio
DTSTAMP:20261121T004430Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:AGN-193408: Phase 1/2 readout est. (NCT04499248)
DESCRIPTION:AGN-193408\, phase 1/2\, Open-Angle Glaucoma.\nStudy: AGN-19340
 8 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension\nEstim
 ated primary completion: April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/agn-193408#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04499248
URL:https://assetmemo.bio/drug/agn-193408#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
